Aducanumab: Appropriate Use Recommendations Update

• DOI: 10.14283/jpad.2022.34
• Publication Date: 2022-03-30T02:44:58Z
• Authors: Jeffrey Cummings; G.D. Rabinovici; A. Atri; P. Aisen; L.G. Apostolova; S. Hendrix; M. Sabbagh; D. Selkoe; M. Weiner; S. Salloway
• Keywords: titration; Aging; Amyloid; Clinical Sciences; Apolipoprotein E4; 610; Neurodegenerative; Alzheimer's Disease; Antibodies, Monoclonal, Humanized; Antibodies; Article; 03 medical and health sciences; 0302 clinical medicine; Clinical Research; Alzheimer Disease; 616; Monoclonal; Acquired Cognitive Impairment; 2.1 Biological and endogenous factors; Humans; Humanized; Cognitive and computational psychology; appropriate use; ARIA; Biomedical and Clinical Sciences; Neurosciences; Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD); aducanumab; Aduhelm; Alzheimer's disease; United States; Brain Disorders; 3. Good health; Neurological; Biological psychology; Dementia; Patient Safety; amyloid imaging; Alzheimer’s disease; MRI

Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer's disease or mild AD dementia. Aducanumab Appropriate Use Recommendations (AURs) have been published and have helped guide best practices for use of aducanumab. As real-world use has occurred and more information has accrued, the AURs require refinement. We update the AURs to better inform appropriate patient selection and improve shared decision-making, safety monitoring, and risk mitigation in treated patients. Based on evolving experience we emphasize the importance of detecting past medical conditions that may predispose to amyloid related imaging abnormalities (ARIA) or may increase the likelihood of ARIA complications including autoimmune or inflammatory conditions, seizures, or disorders associated with extensive white matter pathology. The apolipoprotein E ε4 (APOE4) genotype is strongly associated with ARIA and exhibits a gene dose effect. We recommend that clinicians perform APOE genotyping to better inform patient care decisions, discussions regarding risk, and clinician vigilance concerning ARIA. As most ARIA occurs during the titration period of aducanumab, we suggest performing MRI before the 5th, 7th, 9th, and 12th infusions to improve detection. Uncommonly, ARIA may be recurrent or serious; we suggest additional parameters for treatment discontinuation taking these observations into account. It is important to continue to learn from the real-world use of aducanumab and the AURs will continue to evolve as new information becomes available. This AUR update does not address efficacy, price, or insurance coverage and is provided to assist clinicians to establish best practices for use of aducanumab in the treatment of patients with mild cognitive impairment and mild Alzheimer's dementia.